Major Events - Chery Automobile (09973) has received a subscription rate of 308.18 times for its Hong Kong public offering [1] - Sinopec Oilfield Services (01033) has officially signed a contract for the second phase of the Ratawi oil field and inter-well pipeline project in Iraq [1] - Heng Rui Medicine (01276) has signed a licensing agreement for the Trastuzumab project with Glenmark Specialty [1] - AsiaInfo Technologies (01675) has signed a cooperation contract with Alibaba Cloud for a capability center [1] - Baidu Biotechnology-B (02315) has received approval from the Shanghai Stock Exchange's Science and Technology Innovation Board for its A-share issuance [1] Financial Data - Chow Tai Fook Enterprises (00659) reported a 3.73% year-on-year increase in net profit attributable to shareholders, reaching HKD 2.162 billion, with a final dividend of HKD 0.35 per share [1] - Nine Dragons Paper (02689) reported a 135.4% year-on-year increase in profit attributable to equity holders, amounting to approximately HKD 1.767 billion [1] - Datang New Energy Group (00559) announced an annual profit of HKD 33.614 million, marking a return to profitability [1] Buybacks and Increases - Tencent Holdings (00700) repurchased 858,000 shares at a cost of approximately HKD 550 million on September 24 [1] - Anta Sports (02020) spent HKD 188 million to repurchase 2.003 million shares on September 24 [1] - Midea Group (00300) repurchased 1.3541 million A-shares for approximately HKD 99.9934 million on September 24 [1] - Lianlian Digital (02598) plans to repurchase H-shares in the open market [1] - Giant Bio (02367) saw its controlling shareholder increase holdings by 2.0066 million shares [1] - New天绿色能源 (00956) received an increase of 1 million H-shares from its shareholder, Great Wall Life Insurance [1]

百奥赛图-B(02315)公布，上交所科创板上市委员会2025年第38次审议会议已于 2025年9月24日召开。根 据会议审议结果，公司建议A股发行及于上交所科创板上市已获上交所科创板上市委员会批准。 ...

格隆汇9月24日丨百奥赛图-B(02315.HK)公告，董事会仅此宣布，上交所科创板上市委员会2025年第38 次审议会议已于2025年9月24日召开。根据会议审议结果，公司建议A股发行及于上交所科创板上市已 获上交所科创板上市委员会批准。 ...

智通财经APP讯，百奥赛图-B(02315)公布，上交所科创板上市委员会2025年第38次审议会议已于 2025 年9月24日召开。根据会议审议结果，公司建议A股发行及于上交所科创板上市已获上交所科创板上市 委员会批准。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （股份代號：2315） 內幕消息 建議A股發行 獲上海證券交易所科創板上市委員會批准之公告 本公告由百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）遵照香港聯合交易所 有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及證券及期貨條例（香港法 例第571章）第XIVA部的內幕消息條文（定義見上市規則）而發出。 董事會僅此宣佈，上交所科創板上市委員會2025年第38次審議會議（「會議」）已於 2025年9月24日召開。根據會議審議結果，本公司建議A股發行及於上交所科創板 上市已獲上交所科創板上市委員會批准。 （於中華人民共和國註冊成立的股份有限公司） 茲提述本公司日期為2023年3月6日、2023年3月15日、2023年6月20日及2025年 9月17日的公告及 ...

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to return to A-share market after successfully passing the listing review by the Shanghai Stock Exchange, marking its A+H listing strategy [1] Group 1: Company Overview - Baiaosaitu, established in 2009, is a preclinical CRO and biotechnology company that provides innovative model animals and preclinical drug development services based on its proprietary gene editing technology [1] - The company has developed a comprehensive platform that includes gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1] Group 2: Business Achievements - As of the reporting period, Baiaosaitu has completed over 5,100 customized gene editing projects and developed more than 3,500 types of RenMice and other gene-edited animals and cell line models [2] - The company has established partnerships with numerous renowned biotech and pharmaceutical companies for antibody drug discovery, leveraging its RenMice platform and "thousands of mice, ten thousand antibodies" approach [2] Group 3: Financial Performance - From 2022 to 2024, Baiaosaitu's revenue is projected to be 534 million yuan, 717 million yuan, and 980 million yuan, with a compound annual growth rate of 35.56% [3] - The net profit for the same period is expected to be -602 million yuan, -383 million yuan, and 33.54 million yuan, indicating a turnaround to profitability in 2024 [3] Group 4: IPO and Fundraising - Baiaosaitu plans to raise 1.185 billion yuan through its IPO, which will be directed towards enhancing its existing business and core technologies [3] - The fundraising will support projects aimed at expanding the production capacity of model animals, improving early drug discovery capabilities, and enriching the preclinical research pipeline [3]

在上市委会议上，上市委要求百奥赛图结合全人源抗体小鼠平台的技术先进性，抗体开发业务的市场空 间，研发投入产出情况，从项目测试到转让/授权/合作开发的首付款、里程碑款、药物上市销售分成的 商业模式及目前收入实现情况等，说明抗体开发业务的商业模式稳定性和未来盈利能力。 此外，上市委要求百奥赛图说明若公司本次A股发行上市、实控人减持H股股份，是否影响公司控制权 的稳定性。 北京商报讯（记者 丁宁）上交所官网显示，百奥赛图（北京）医药科技股份有限公司（以下简称"百奥 赛图"）科创板IPO上会获通过。 ...

值得一提的是，百奥赛图的发展也离不开大兴区的产业土壤。作为北京生物医药产业的集聚高地，大兴 区不断加快"国际生命健康产业创新区"建设步伐，打造从研发、孵化到产业化的全链条生态。大兴政府 为百奥赛图提供了良好的政策环境与产业配套，从研发平台到人才队伍建设，都给予了积极支持。百奥 赛图也因此能够依托大兴，放眼全球，在创新药领域持续深耕。 "我们不只是一家小鼠公司。"正如百奥赛图董事长沈月雷所言，公司不仅提供靶点人源化小鼠，更通过 候选抗体分子授权，形成指数型增长的业务模式。随着抗体分子库的不断扩充，百奥赛图正在筑起更高 的行业壁垒，向着"全球新药发源地"这一目标稳步迈进。 当前，国家层面对生物医药产业的支持力度空前，鼓励更多企业走出国门、面向国际市场。百奥赛图作 为从大兴走向世界的代表企业，正是这一政策导向下的典型缩影。它不仅以创新技术填补了我国新药研 发的底层短板，也在全球创新药产业链中展现出"中国方案"的独特价值。 在国家大力推动生物医药产业高质量发展的今天，生物医药被正式纳入战略性新兴产业和未来产业重点 布局方向。政策层面不断强调加快新药研发、完善创新生态、支持关键技术突破，这为行业带来前所未 有的发展机遇 ...

Core Viewpoint - The Chinese biopharmaceutical industry is undergoing a profound structural transformation, with innovative companies becoming the backbone of high-quality development in the sector [1][8]. Group 1: Industry Recovery - The global biopharmaceutical industry is emerging from a period of tightened capital and stricter regulations, presenting new growth opportunities for innovative drug companies [2]. - In the first half of 2025, the company reported impressive results, achieving revenue of 621 million yuan, a year-on-year increase of 51.5%, and a net profit of 48 million yuan, surpassing the total for the previous year [2]. - The company’s operating cash flow turned positive with a net inflow of 203 million yuan, and R&D investment grew nearly 30% to 209 million yuan, reflecting a trend of industry recovery and the maturation of the company's business model [2]. Group 2: Dual-Engine Growth Model - The company's growth is driven by a dual-engine business model, with the humanized mouse business showing a 56% year-on-year revenue increase and a gross margin of 79%, solidifying its status as a cash cow [3]. - The "thousand mice, ten thousand antibodies" initiative, focusing on the development of fully human antibody molecules, signed approximately 80 new collaborations in the first half of the year, a 60% increase year-on-year, with a gross margin close to 90% [3]. - This innovative business model transforms the traditionally high-risk, long-cycle antibody discovery process into standardized, scalable "shelf-type antibody products," significantly enhancing drug development efficiency [3][4]. Group 3: Globalization and Innovation - The company has established a global network with operational centers in key locations such as Boston, San Francisco, and Heidelberg, enhancing its collaboration capabilities with major pharmaceutical companies [5][6]. - The company has applied for over 400 patents, showcasing its technological strength and providing robust intellectual property protection for international collaborations [5]. - The favorable innovation ecosystem in Daxing District, supported by government policies and infrastructure, has facilitated the company's growth and international expansion [7][8]. Group 4: Future Outlook - The biopharmaceutical industry is a crucial component of the national strategic emerging industries, and the company’s success reflects the solid progress of the biopharmaceutical sector in Daxing [8]. - As Daxing continues to optimize its industrial ecosystem and international cooperation mechanisms, more innovative companies like the subject company are expected to emerge and contribute to the high-quality development of China's biopharmaceutical industry [8].

在肿瘤治疗的百年探索史中，很少有一个概念能像"Magic bullets（魔法子弹）"一样承载如此多的想 象。1913年，德国科学家保罗·埃尔利希提出，要找到一种能够精准打击病灶、不伤害正常细胞的理想 药物。一个世纪之后，这一设想在抗体偶联药物（ADC）上逐渐变为现实。 在这股浪潮中，一家中国Biotech的身影格外醒目——百奥赛图。 破解研发痛点：从稳定性到效率 2024年底，百奥赛图与德国Tubulis达成合作，将基于其RenMice®平台授权的抗体序列，与Tubulis专有 连接子与有效载荷技术相结合，共同开发新一代ADC疗法。公司有权获得首付款、里程碑付款及未来 销售分成。这只是其全球布局的一个缩影。 更具代表性的案例来自与IDEAYA Biosciences的合作。IDEAYA在2024年底引进了百奥赛图的B7- H3/PTK7双抗ADC项目IDE034，交易金额接近30亿元人民币。该分子通过百奥赛图独有的RenLite平台 筛选得到，能同时识别B7-H3与PTK7两个靶点，在肺癌、结直肠癌、头颈癌等多种实体瘤中高度共表 达。在临床前研究中，IDE034展现出显著的抑瘤效果，并与IDEAYA的PAR ...